First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and ...

Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

“All we can do now is give them trazodone two hours before a storm and try to comfort them,” Cantwell said. Anti-anxiety ...

R&D expense was $11.7 million for the three months ended June 30, 2025, compared to $7.6 million for the same period in 2024. The increase was primarily driven by higher research, development, ...

Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...

Newly developed DNA nanostructures can form flexible, fluid, and stimuli-responsive condensates without relying on chemical ...

In the most severe erosive esophagitis patients (LA grade C or D), tegoprazan 100mg was found to be statistically superior to lansoprazole for maintenance of healing at 24 weeks. Noninferiority vs ...

The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by ...